This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Assessment of clinical probability of pulmonary embolism (PE)

Authoring team

In patients with suspected PE, a clinical or pre-test probability assessment could be carried out based on the risk factors and clinical features

  • it will assess the clinical likelihood of PE in a patient
  • the assessment can be carried out either by implicit clinical judgement or by the use of a validated clinical prediction rule e.g.- Canadian rule, by Wells et al or the revised Geneva rule

The Canadian rule by Wells et al divides a person's clinical probability of pulmonary embolism into:

  • three-category scheme - low, moderate or high clinical probability
  • two-category scheme - PE likely or PE unlikely (2)

The revised Geneva rule also divides the clinical probability of PE in to low, intermediate and high (2). Which ever rule is used the prevalence of PE is about:

  • 10% - in patients with a low clinical probability
  • 30% - in those with a moderate clinical probability
  • 65% - in those with a high clinical probability

Concurrent use of a D-dimer test with the pre test clinical probability score is recommended. e.g. - when a negative d-dimer result is used together with a low or intermediate pre test clinical probability score, it has a 92% sensitivity at excluding pulmonary embolism (3)

A schemata for assessment has been suggested (4)

 

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.